COLLTECH
biomaterials innovation

28 May 2007

Dear Shareholder,

GENERAL MEETING

I am pleased to invite you to attend a general meeting of CollTech Australia Limited to be held Friday 29th June 2007 (refer to attached notice of meeting for details) and provide you with an update on CollTech Australia Ltd.

CollTech is beginning a significant growth phase with cosmetic grade products recently commercialised and future high margin research and medical products close to market launch. To assist Colltech to capitalise on these opportunities we are currently raising $1.5million to grow our marketing and sales presence in the high volume Asian, USA and European markets as well as fund the continued development of the Research and Medical OVICOLL® products.

CollTech Australia is poised to capitalise on its founding directors vision when they listed the company in February 2004: *"To be a world-leading supplier of quality biomaterials specialising in the production and sale of high-grade ovine collagen."*

Since then the company has built and commissioned a state-of-the-art manufacturing facility and developed and patented a unique process to extract collagen from sheepskins. Recently CollTech launched OVICOLL®|C and OVICOLL®|Clear into the cosmetics market. To enhance market acceptance of these products, CollTech has successfully completed independent clinical testing verifying their non-irritant and high moisturising characteristics. CollTech is also actively pursuing Halal certification to further expand the market opportunities for OVICOLL®.

Current Focus on Sales of OVICOLL

CollTech has recently signed up a distributor for Thailand and is currently finalising a number of negotiations for distribution throughout South East Asia, Korea, China, USA and Europe. These opportunities have arisen from the successful launch of our ovine collagen at PCIA (China), In Cosmetics (Paris) and NYSCC Suppliers Day (New Jersey). Interest in our unique product is building daily and we anticipate significant sales growth throughout 2007.

OVICOLL® for Research and Medical applications represent the next steps in CollTech's development pipeline and the starting material for these has already been realised in the form of OVICOLL®|Clear. CollTech is currently ahead of schedule with its research and medical grade development program and received promising feedback at the worlds largest Biotechnology conference, BIO2007 in Boston USA earlier this month. Prototype products including medical sponges and membranes were available for evaluation and companies who had dismissed the use of mammalian collagen due to the disease issues (mad cow) are keen to revisit development using OVICOLL®.

With a low risk product replacement strategy in an established bio-industrial market and prior product manufacturing challenges resolved, major risks for CollTech have been overcome. This placement provides an opportunity for CollTech to grow its marketing and sales presence in the high volume Asian and European markets as well as fund the further development of the Research and Medical OVICOLL® products.

If you are unable to attend the meeting in person, I encourage you to still participate by lodging the proxy form included with the Notice of Meeting. The proxy form can be returned to CollTech at the address below or sent by fax to 08 9426 3909. To be valid your proxy must be received by CollTech no later than 12 noon on Wednesday 27th June 2007.

I look forward to your continued involvement with the Company.

Yours faithfully

Stephen Carter
CHAIRMAN

COLLTECH
biomaterials innovation

NOTICE OF GENERAL MEETING

THIS IS AN IMPORTANT DOCUMENT
AND REQUIRES YOUR ATTENTION

If you are in doubt as to how to deal with it,
please consult your financial or other professional adviser.

NOTICE OF GENERAL MEETING

COLLTECH AUSTRALIA LTD

ABN 24 094 515 992

Incorporating

Explanatory Memorandum and Proxy Form

Notice is given that a General Meeting of CollTech Australia Limited will be held at

The Celtic Club,
48 Ord Street, West Perth, Western Australia 6005.

On Friday, 29th June 2007 at 12 noon WST

INSTRUCTIONS TO SHAREHOLDERS

Venue

A General Meeting of the Shareholders of CollTech Australia Ltd will be held at:

The Celtic Club,
48 Ord Street, West Perth, Western Australia 6005.

Commencing at

12 noon (WST) on Friday, 29th June 2007. Registration for meeting from 11.45 a.m.

How to Vote

You may vote by attending the meeting in person, by proxy or authorised representative.

Voting in Person

To vote in person, attend the meeting on the date and at the place set out above. The meeting will commence at 12 noon.

Voting by Proxy

To vote by proxy, please complete and sign the proxy form enclosed with this notice as soon as possible and either:

1. return the proxy form by post to CollTech Australia Ltd PO Box 1264, West Perth WA 6872,
2. or send the proxy by facsimile to the Company on facsimile number (+61 8) 9426 3909,

so that it is received not later than 12 noon (WST) on Wednesday the 27th of June 2007.

Your proxy form is enclosed.

Enquiries

The Company welcomes enquiries in respect of matters covered in this Notice of Meeting and Explanatory Memorandum of the General Meeting proposed. Should you require further information please contact:

<u>Chairman</u>
Stephen Carter
Phone: (+61 8) 9426 3900
Fax: (+61 8) 9426 3909
Email: scarter@colltech.com.au

or

<u>Company Secretary</u>
Glen Brune
Phone: (+61 8) 9426 3900
Fax: (+61 8) 9426 3909
Email: gbrune@colltech.com.au

NOTICE OF GENERAL MEETING

Notice is hereby given that a General Meeting of the members of CollTech Australia Ltd ("**Company**") will be held at The Celtic Club, 48 Ord Street, West Perth, Western Australia on Friday 29th June 2007 at 12 noon (WST) for the purpose of transacting the following business.

An Explanatory Memorandum containing information in relation to each of the following Resolutions accompanies and forms part of this Notice of Meeting. Terms used in this Notice of Meeting have the meaning given to them in the glossary contained in the Explanatory Memorandum.

BUSINESS OF THE GENERAL MEETING

RESOLUTION 1:

ELECTION OF DIRECTOR – MR GREGG MASTROIANNI

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

"That Mr Gregg Mastroianni, a director appointed as an addition to the existing Directors and being eligible for election be elected as a Director of the Company."

RESOLUTION 2:

RATIFICATION OF ISSUE OF OPTIONS TO CHIEF FINANCIAL OFFICER, MR GLEN BRUNE

To consider and, if thought fit, to pass the following resolution as an **ordinary resolution**:

"That, for the purposes of ASX Listing Rule 7.4 and all other purposes, the Company approves and ratifies the grant, for no issue price, of 650,000 Options to Glen Brune or his nominee, each option being exercisable at 10 cents and expiring on 9 February 2010, and otherwise granted in accordance with the terms and conditions set out in Annexure A to the Explanatory Memorandum forming part of this Notice of Meeting."

The Company will disregard any votes cast on Resolution 2 by any person who participated in the grant of Options or any person associated with those persons. However, the Company need not disregard a vote if it is cast by a person as proxy for a person who is entitled to vote, in accordance with the directions on the proxy form or it is cast by the person chairing the meeting as proxy for a person who is entitled to vote, in accordance with a direction on the proxy form to vote as the proxy decides.

RESOLUTION 3:

RATIFICATION OF ISSUE OF OPTIONS TO OPERATIONS MANAGER, MR STEWART WALTON

To consider and, if thought fit, to pass the following resolution as an **ordinary resolution**:

"That, for the purposes of ASX Listing Rule 7.4 and all other purposes, the Company approves and ratifies the grant, for no issue price, of 650,000 Options to Stewart Walton or his nominee, each option being exercisable at 10 cents and expiring on 9 February 2010, and otherwise granted in accordance with the terms and conditions set out in Annexure A to the Explanatory Memorandum forming part of this Notice of Meeting."

The Company will disregard any votes cast on Resolution 3 by any person who participated in the grant of Options or any person associated with those persons. However, the Company need not disregard a vote if it is cast by a person as proxy for a person who is entitled to vote, in accordance with the directions on the proxy form or it is cast by the person chairing the meeting as proxy for a person who is entitled to vote, in accordance with a direction on the proxy form to vote as the proxy decides.

RESOLUTION 4:

RATIFICATION OF PLACEMENT OF SHARES – LISTING RULE 7.4

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

"That, for the purposes of ASX Listing Rule 7.4 and all other purposes, the Company approve and ratify the issue of 18,491,991 *Shares in the Company at an issue price of 6 cents each to the parties specified in, and on such terms and conditions set out in the Explanatory Memorandum forming part of this Notice of Meeting."*

The Company will disregard any votes cast on Resolution 4 by any person who participates and/or obtains a benefit in the grant of Shares or any person associated with those persons. However, the Company need not disregard a vote if it is cast by a person as proxy for a person who is entitled to vote, in accordance with the directions on the proxy form or it is cast by the person chairing the meeting as proxy for a person who is entitled to vote, in accordance with a direction on the proxy form to vote as the proxy decides.

RESOLUTION 5:

APPROVAL OF SHARE ISSUE – LISTING RULE 7.1

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

"That, for the purposes of ASX Listing Rule 7.1 and all other purposes, the Company approve the issue of 7,264,675 *Shares in the Company at an issue price of 6 cents each to the parties specified in, and on such terms and conditions set out in the Explanatory Memorandum forming part of this Notice of Meeting."*

The Company will disregard any votes cast on Resolution 5 by any person who participates and/or obtains a benefit in the grant of Shares or any person associated with those persons. However, the Company need not disregard a vote if it is cast by a person as proxy for a person who is entitled to vote, in accordance with the directions on the proxy form or it is cast by the person chairing the meeting as proxy for a person who is entitled to vote, in accordance with a direction on the proxy form to vote as the proxy decides.

RESOLUTION 6:

APPROVAL OF SHARE ISSUE TO RELATED PARTY – LISTING RULE 10.11

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

"That, for the purposes of ASX Listing Rule 10.11 and all other purposes, the Company approve and ratify the issue of 1,000,000 Shares in the Company at an issue price of 6 cents each to Mr Michael Pixley, Director, specified in, and on such terms and conditions set out in the Explanatory Memorandum forming part of this Notice of Meeting."

The Company will disregard any votes cast on Resolution 6 by any person who participates and/or obtains a benefit in the grant of Shares or any person associated with those persons. However, the Company need not disregard a vote if it is cast by a person as proxy for a person who is entitled to vote, in accordance with the directions on the proxy form or it is cast by the person chairing the meeting as proxy for a person who is entitled to vote, in accordance with a direction on the proxy form to vote as the proxy decides.

By order of the Board

Glen Brune
Company Secretary
Dated: 28th May 2007

EXPLANATORY MEMORANDUM

This Explanatory Memorandum is intended to provide Shareholders with sufficient information to assess the merits of the Resolutions contained in the accompanying Notice of General Meeting of the Company, of which this Explanatory Memorandum forms part.

The directors of the Company recommend Shareholders read this Explanatory Memorandum in full before making any decision in relation to the resolutions.

ITEM 1 – RESOLUTION 1 - ELECTION OF DIRECTOR, MR GREGG MASTROIANNI

Mr Mastroianni was appointed Director of the Company in April 2007. In accordance with the Company's constitution his appointment is to be confirmed at the first General Meeting following his appointment.

Mr. Mastroianni brings to the board over thirty-five years of international sales and marketing experience in the health sciences industry, including twenty-seven years with health care giant Johnson and Johnson (J&J). Gregg is currently Vice President of Sales and Marketing for Brisbane-based AGEN Biomedical, a wholly owned division of Agenix Limited (ASX: AGX).

Mr Mastroianni has previously held positions of Vice President Sales and Marketing (JM Kyriakidis, Greece), Director Export Sales and Marketing (J&J United Kingdom), Director of International Distributor Sales (J&J USA) and Marketing Director (J&J Japan) as well as a number of other relevant senior management positions. During this time he has developed extensive skills in developing new markets, establishing successful distribution channels, Business to Business (B2B) operations management and managing sales teams to provide improved performance whilst increasing margins and volumes. Gregg also brings to the board extensive skills in B2B contract negotiation and creation and implementation of technology transfer programs.

ITEM 2 - RESOLUTION 2 AND 3 – RATIFICATION OF PREVIOUS ISSUE OF OPTIONS

Listing Rule 7.1 provides that a listed company may not issue securities in any 12 month period where the total number of securities to be issued exceeds 15% of the number of fully paid ordinary securities on issue 12 months before the date of issue except with the prior approval of members of the company, in a general meeting, of the terms and conditions of the proposed issue.

Listing Rule 7.4 provides that an issue of securities made without approval under Listing Rule 7.1 is treated as having been made with approval for the purpose of Listing Rule 7.1 if the issue did not breach Listing Rule 7.1 at the time of issue and Shareholders subsequently approve the issue.

Resolution 2 seeks Shareholder approval subsequently for the purpose of Listing Rule 7.4 to the issue of 650,000 Options on 9 February 2007 to Mr Glen Brune, the Chief Financial Officer of the Company, at no cost. The Options were issued by way of employee incentives to Mr Brune. The 650,000 Options have an exercise price of 10 cents each and an expiry date of 9 February 2010. A copy of the terms of the Options is attached as Annexure A to this Explanatory Memorandum. No funds were raised by the grant of the Options.

Resolution 3 seeks Shareholder approval subsequently for the purpose of Listing Rule 7.4 to the issue of 650,000 Options on 9 February 2007 to Mr Stewart Walton the Operations Manager of the Company, at no cost. The Options were issued by way of employee incentives to Mr Walton. The 650,000 Options have an exercise price of 10 cents each and an expiry date of 9 February 2010. A copy of the terms of the Options is attached as Annexure A to this Explanatory Memorandum. No funds were raised by the grant of the Options.

Shareholder approval to Resolutions 2 and 3 will re-instate the number of securities available to be issued by the Company under Listing Rule 7.1 without Shareholder approval by the amount of 1,300,000.

ITEM 3 - RESOLUTION 4 – RATIFICATION OF PLACEMENT OF SHARES

Prior to the General Meeting, the Company will complete a placement of Shares to certain institutional and professional investors at an issue price of 6 cents per Share ***("Placement")***.

The issue price represents a 9.2% discount to the Company's volume weighted average price over the 5 days prior to 14 May 2007. The Company will issue 18,491,991 Shares under the Placement prior to the General Meeting.

Resolution 4: has been included so that Shareholders may approve and ratify pursuant to Listing Rule 7.4 the issue of the 18,491,991 Shares under the Placement, for the purpose of restoring the Company's capacity to issue subsequent securities without further Shareholder approval.

For the purpose of Listing Rule 7.5, the following information is provided:

1. the number of Shares that will have been allotted and issued will be 18,491,991;
2. the Shares will have been issued at an issue price of 6 cents;
3. the Shares issued will be ordinary fully paid shares in the capital of the Company and rank equally in all respects with the existing ordinary fully paid shares issued in the capital of the Company;
4. the Shares will be allotted to certain institutions and professional investors, being qualified clients of BBY Limited; and
5. the funds raised will be used by the Company to achieve the Sales and Marketing goals for OVICOLL cosmetic Collagens and continue the research and development to advance the development of the Company's biomedical collagen products and for general working capital purposes.

ITEM 4 - RESOLUTION 5 – APPROVAL OF PLACEMENT OF SHARES

The Company intends to complete a placement of Shares to certain institutional and professional investors at an issue price of 6 cents per Share ***("Placement")***.

The Company intends to issue 7,264,675 Shares under the Placement with the Shares being issued prior to 31 July 2007.

Resolution 5: has been included so that Shareholders may approve pursuant to Listing Rule 7.1 the issue of the 7,264,675 Shares under the Placement.

For the purpose of Listing Rule 7.3, the following information is provided:

1. the number of Shares to be issued is 7,264,675;
2. the Shares will be issued prior to 31 July 2007;
3. the Shares are to be issued at an issue price of 6 cents;
4. the Shares will be allotted to certain institutions and professional investors, being qualified clients of BBY Limited;
5. the Shares issued will be ordinary fully paid shares in the capital of the Company and rank equally in all respects with the existing ordinary fully paid shares issued in the capital of the Company; and
6. the funds raised will be used by the Company to achieve the Sales and Marketing goals for OVICOLL cosmetic Collagens and continue the research and development to advance the development of the Company's biomedical collagen products and for general working capital purposes.

ITEM 5 - RESOLUTION 6 – APPROVAL OF PLACEMENT OF SHARES TO RELATED PARTY

The Company intends to complete a placement of Shares in the Company to a related party at an issue price of 6 cents per Share ***("Placement")***.

The Company intends to issue 1,000,000 Shares under the Placement with the Shares being issued prior to 31 July 2007 to a related party.

Resolution 6: has been included so that Shareholders may approve pursuant to Listing Rule 10.11 the issue of the 1,000,000 Shares to Mr Michael Pixley, Director, under the Placement.

For the purpose of Listing Rule 10.11, the following information is provided:

1. the number of Shares to be issued is 1,000,000;
2. the Shares will be issued prior to 31 July 2007;
3. the Shares are to be issued at an issue price of 6 cents;
4. the Shares issued will be ordinary fully paid shares in the capital of the Company and rank equally in all respects with the existing ordinary fully paid shares issued in the capital of the Company; and
5. the funds raised will be used by the Company to achieve the Sales and Marketing goals for OVICOLL cosmetic Collagens and continue the research and development to advance the development of the Company's biomedical collagen products and for general working capital purposes.

NOTES

1. In accordance with Regulation 7.11.37 of the Corporations Regulations, the Directors have set a snapshot time and date to determine the identity of those entitled to attend and vote at the Meeting. The snapshot time and date is 5.00 pm (WST) on Wednesday 27th June 2007.
2. A proxy form is attached. If required it should be completed, signed and returned to the Company's registered office in accordance with the proxy instructions on that form.

GLOSSARY

In this Explanatory Memorandum and the Notice, the following terms have the following meanings unless the context otherwise requires:

TERM	**DEFINITION**
ASIC	Australian Securities and Investments Commission.
ASX	Australian Securities Exchange Limited ACN 008 624 691.
Board	The Board of Directors of the Company.
Company	CollTech Australia Limited ABN 24 094 515 992.
Constitution	The constitution of the Company.
Corporations Act	Corporations Act 2001.
Director	A director of the Company.
$	Australian dollars unless otherwise stated.
Eligible Shareholders	All Shareholders of the Company who are registered as holding Shares on the 27th June 2007 @ 5:00pm (WST).
Employee	An employee of the Company.
Listing Rules	The Listing Rules of ASX.
Notice	The Notice of Meeting accompanying this Explanatory Memorandum.
Option	An option to acquire a Share.
Share	A fully paid ordinary share in the capital of the Company.
WST	Australian Western Standard Time.

ANNEXURE A

TERMS AND CONDITIONS OF OPTIONS

1. Each Option entitles the Option holder to subscribe for one Share.
2. The exercise price for each Option is 10 cents ("**Exercise Price**").
3. The Option holder may exercise the Options at any time from date of grant until 3 years after the date of grant, upon which they will expire ("**Expiry Date**").
4. The Options may be exercised by the Option holder providing the Company with written notice and payment of the Exercise Price for each Option being exercised. The Company must then allot the appropriate number of Shares to the Option holder within 10 Business Days.
5. The Options are not assignable or transferable other than to a company or trust controlled by the Option holder.
6. Any unexercised Option does not entitle the Option holder to any voting rights or the right to participate in rights or bonus issues made by the Company.
7. The Options will not be quoted on the ASX.
8. If there is a bonus issue to holders of Shares ("**Bonus Issue**"), the number of Shares over which an Option is exercisable will be increased by the number of Shares which the Option holder would have received if the Option had been exercised prior to the record date for determining entitlements to the Bonus Issue ("**Bonus Shares**"). The Bonus Shares will be paid up out of the profits or reserves of the Company in the same manner as is applied in the Bonus Issue and will, from time to time, rank pari passu with all other Shares on issue.
9. If there is a pro rata issue (other than a Bonus Issue) to holders of Shares during the currency of, and prior to the exercise of, any Options, the exercise price of the Options will be adjusted in the manner provided by the ASX Listing Rules, even if the Company is not admitted to the Official List.
10. If, prior to the expiration of any Options, there is a reorganisation of the issued capital of the Company (including, but not limited to, a consolidation, subdivision, share split, cancellation, reduction or return of capital), the rights of the Option holder will be changed to the extent necessary to comply with the ASX Listing Rules.
11. If at any time the Option holder (or where the Option holder is a nominee, the person entitled to appoint that nominee):
    (a) has been dismissed or removed from office for a reason which, in the reasonable opinion of the Board, entitles the Company to dismiss the person without notice;
    (b) has committed, in the reasonable opinion of the Board, an act of fraud, defalcation or gross misconduct in relation to the affairs of the Company (whether or not charged with an offence); or
    (c) has, in the reasonable opinion of the Board, done an act which brings the Company into disrepute,

    all Options held by the Option holder not vested will immediately lapse and all rights in respect of those Options will cease.
12. The Options are otherwise issued under the terms of the CollTech Australia Limited Option holder Share Option Plan approved by the Board on 27 November 2003.

COLLTECH
biomaterials innovation

PROXY FORM

The Company Secretary
CollTech Australia Limited
Registered Office:
PO Box 1264
WEST PERTH WA 6872 Facsimile: (08) 9426 3909

I/We (name of Shareholder) ....

of (address) ....

being a member/members of CollTech Australia Limited HEREBY APPOINT

(name) ....

of (address) ....

and/or failing him (name) ....

of (address) ....

or failing that person then the Chair of the meeting as my/our proxy to vote on my/our behalf at the General Meeting of the Company held on Friday, 29th June 2007 at 12 noon WST and at any adjournment of the meeting.

Should you so desire to direct the Proxy how to vote, you should place a cross in the appropriate box(es) below:

I/We direct my/our Proxy to vote in the following manner:

		For	Against	Abstain
Resolution 1	Election of Director – Gregg Mastroianni	☐	☐	☐
Resolution 2	Ratification of issue of Options – Mr Glen Brune	☐	☐	☐
Resolution 3	Ratification of issue of Options – Mr Stewart Walton	☐	☐	☐
Resolution 4	Ratification of Share Issue – Listing Rule 7.4	☐	☐	☐
Resolution 5	Approval of Share Issue – Listing Rule 7.1	☐	☐	☐
Resolution 6	Approval of Share Issue to Related Party - Listing Rule 10.11	☐	☐	☐

If the Chair of the meeting is appointed as your proxy, or may be appointed by default and you do not wish to direct your proxy how to vote as your proxy in respect of a resolution please place a mark in this box. ☐

If no directions are given my proxy may vote as the proxy thinks fit or may abstain.

The Chairperson intends to vote any undirected proxies in favour of the Resolutions.

Dated: ______________________ 2007.

This Proxy is appointed to represent ______% of my voting right, or if 2 proxies are appointed Proxy 1 represents ______% and Proxy 2 represents ______% of my total votes

My total voting right is ____________shares.

If the Shareholder is an individual:

Signature: ________________________________ **Name:**________________________________

If the Shareholder is a company: (Affix common seal if required by Constitution)

________________________________ ________________________________

Director/Sole Director and Secretary **Director/Secretary**

INSTRUCTIONS FOR APPOINTMENT OF PROXY

1. A Shareholder entitled to attend and vote is entitled to appoint no more than two proxies to attend and vote at this General Meeting as the Shareholder's proxy. A proxy need not be a Shareholder of the Company.
2. Where more than one proxy is appointed, each proxy must be appointed to represent a specific proportion of the Shareholder's voting rights. If such appointment is not made then each proxy may exercise half of the Shareholder's voting rights. Fractions shall be disregarded.
3. The proxy form must be signed personally by the Shareholder or his attorney, duly authorised in writing. If a proxy is given by a corporation, the proxy must be executed under either the common seal of the corporation or under the hand of an officer of the Company or its duly authorised attorney. In the case of joint shareholders, this proxy must be signed by at least one of the joint shareholders, personally or by a duly authorised attorney.
4. If a proxy is executed by an attorney of a Shareholder, then the original of the relevant power of attorney or a certified copy of the relevant power of attorney, if it has not already been noted by the Company, must accompany the proxy form.
5. To be effective, forms to appoint proxies must be received by the Company no later than 48 hours before the time appointed for the holding of this General Meeting **that is by 12 noon WST on Wednesday 27th June 2007,** by post or facsimile to the respective addresses stipulated in this proxy form:
   (a) the Company on facsimile number (08) 9426 3909 (International: +61 8 9426 3909); or
   (b) the registered office of the Company at Ground Floor, 76 Kings Park Road, West Perth, WA, 6005 or by mail to PO Box 1264, West Perth, WA 6872.
6. If the proxy form specifies a way in which the proxy is to vote on any of the resolutions stated above, then the following applies:
   (a) the proxy need not vote on a show of hands, but if the proxy does so, the proxy must vote that way; and
   (b) if the proxy has 2 or more appointments that specify different ways to vote on the resolution, the proxy must not vote on a show of hands; and
   (c) if the proxy is Chairperson, the proxy must vote on a poll and must vote that way, and
   (d) if the proxy is not the Chairperson, the proxy need not vote on a poll, but if the proxy does so, the proxy must vote that way.

   If a proxy is also a Shareholder, the proxy can cast any votes the proxy holds as a shareholder in anyway that the proxy sees fit.
7. The Chairperson intends to vote any undirected proxies in favour of the resolutions.

Shareholders should direct their enquiries to the Company Secretary of the Company on ph(08)9426 3900, facsimile (08)9426 3909 or email at proxy@colltech.com.au.